MetaCap

Gossamer Bio (GOSS) vs Medicinova (MNOV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicinova (MNOV) has outperformed Gossamer Bio (GOSS) over the past year, losing 8.4% versus a loss of 95.6%. Over five years, MNOV leads with a -59.3% price change compared with -98.7% for GOSS. Medicinova is the larger company by market cap ($67.1 million vs $65.6 million), about 1.0 times the size.

Gossamer Bio converts more of its revenue into profit, with a net margin of -351.5% versus -2928.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOSS-95.62%MNOV-8.39%
+153%+22%-108%
Nov 21, 20251 yearNov 20, 2026
GOSS-98.84%MNOV-59.19%
+30%-38%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOSS versus MNOV key metrics
MetricGOSSMNOV
Share price$10.72$1.31
Market cap$65.57M$67.11M
1-day change-4.54%+3.15%
YTD return-95.68%0.00%
1-year return-95.62%-8.39%
5-year return-98.74%-59.32%
EPS (TTM)$-42.41$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$48.47M$409.66K
Revenue growth (YoY)-57.74%—
Net income (latest FY)$-170.37M$-12.00M
Operating margin-352.23%-3242.47%
Net margin-351.49%-2928.78%
52-week high$309.60$3.90
52-week low$8.29$1.22
Distance from 52-week high-96.54%-66.41%
Analyst consensusbuystrong_buy
Avg. price target upside+669.40%+529.77%
Average volume243.40K334.96K
Shares outstanding6.12M51.23M
Employees1616
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNOV has outperformed GOSS by 87.2 percentage points over the past year.
  • Gossamer Bio is more profitable, keeping -351.5 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.

About Gossamer Bio

GOSS stock →

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

GOSS vs MNOV FAQ

Which is bigger, Gossamer Bio or Medicinova?

Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $65.57M for Gossamer Bio (GOSS).

Which stock has performed better over the past year, GOSS or MNOV?

MNOV returned -8.39% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.

Are Gossamer Bio and Medicinova in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons